There are 410 resources available
5O - Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: Longer follow-up results from the phase III EMPOWER-Lung 3 trial
Presenter: Tamta Makharadze
Session: Proffered Paper 2
Resources:
Abstract
Slides
Webcast
Invited Discussant 84O and 5O
Presenter: Antonio Passaro
Session: Proffered Paper 2
Resources:
Slides
Webcast
Q&A
Presenter: Martin Reck
Session: Proffered Paper 2
Resources:
Webcast
6O - CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy
Presenter: Joel Neal
Session: Proffered Paper 2
Resources:
Abstract
161O - RESILIENT part 2: A randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer (SCLC)
Presenter: Charles Rudin
Session: Proffered Paper 2
Resources:
Abstract
Slides
Webcast
Invited Discussant 6O and 161O
Presenter: Enriqueta Felip
Session: Proffered Paper 2
Resources:
Slides
Webcast
Q&A
Presenter: Noemi Reguart Aransay
Session: Proffered Paper 2
Resources:
Webcast
Welcome and introduction
Presenter: Alfredo Addeo
Session: Janssen Pharmaceuticals - Exploring clinical perspectives in advanced EGFR-mutant NSCLC: How far we have come
Resources:
Webcast
Translating data into clinical practice in EGFR-mutant NSCLC
Presenter: Zopia Piotrowska
Session: Janssen Pharmaceuticals - Exploring clinical perspectives in advanced EGFR-mutant NSCLC: How far we have come
Resources:
Webcast
Practical data applications in EGFR exon20ins-mutant NSCLC
Presenter: Nicolas Girard
Session: Janssen Pharmaceuticals - Exploring clinical perspectives in advanced EGFR-mutant NSCLC: How far we have come
Resources:
Webcast